Literature DB >> 21064095

Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer.

Yong Jung Song1, Joo-Young Kim, Su-Kyoung Lee, Hyun-Sun Lim, Myong Cheol Lim, Sang-Soo Seo, Sokbom Kang, Dong Ock Lee, Sang-Yoon Park.   

Abstract

Human papillomavirus (HPV) DNA is considered as a hallmark of cervical cancer. We investigated whether persistent HPV DNA at the cervix is associated with local recurrence after radiotherapy in patients with locally advanced cervical cancer. A total of 156 patients with HPV-positive cervical cancer (International Federation of Gynecology and Obstetrics stage IB-IVB) treated with radiotherapy between July 2003 and December 2006 were analyzed. HPV DNA was measured prior to radiotherapy and after completion of radiotherapy. The results of HPV DNA test at postradiotherapy 1, 3, 6 and 12 months were analyzed individually for association with local recurrence-free survival (LRFS). In addition, the result of any last follow-up HPV test within 24 months postradiotherapy was defined as the overall status of HPV at 24 months and was also analyzed for association with LRFS. HPV DNA was cleared in 127 patients (81.4%) and persistent in 29 patients (18.6%) by 24 months. In 18 patients with local recurrences, 14 patients (78%) showed positive HPV tests at 1-3 months. Among the various time points analyzed, a positive HPV test at 3 months was the most accurate predictor of local recurrence. Multivariate analysis indicated that overall status of HPV at 24 months, low HPV viral load and histologic grade as being significantly related to poor LRFS. In HPV-positive cervical carcinoma treated primarily with radiotherapy, persistent HPV DNA within 24 months after treatment indicates a high risk of local recurrence. Diagnostic accuracy of HPV test was highest at 3 months.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21064095     DOI: 10.1002/ijc.25741

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  A report of human papilloma virus-16 associated vaginal carcinoma after thirty-two years of successful radiation therapy for cervical cancer.

Authors:  Gazal Jain; Sasidharanpillai Sabeena; Akhila Vasudeva; Anjali Mundkur; Srilatha Parampalli Srinivas; G Arunkumar; Pratap Kumar
Journal:  Virusdisease       Date:  2018-08-03

2.  Undetected human papillomavirus DNA and uterine cervical carcinoma: Association with cancer recurrence.

Authors:  Kae Okuma; Hideomi Yamashita; Terufumi Yokoyama; Keiichi Nakagawa; Kei Kawana
Journal:  Strahlenther Onkol       Date:  2016-01       Impact factor: 3.621

3.  Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer.

Authors:  Pippa F Cosper; Christopher McNair; Iván González; Nathan Wong; Karen E Knudsen; Jason J Chen; Stephanie Markovina; Julie K Schwarz; Perry W Grigsby; Xiaowei Wang
Journal:  Int J Cancer       Date:  2019-12-04       Impact factor: 7.396

4.  Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update.

Authors:  L Elit; E B Kennedy; A Fyles; U Metser
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

5.  A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.

Authors:  Yasmin Hasan; Larissa Furtado; Ana Tergas; Nita Lee; Rebecca Brooks; Anne McCall; Daniel Golden; Shruti Jolly; Gini Fleming; Matthew Morrow; Kimberly Kraynyak; Albert Sylvester; Fauzia Arif; Matt Levin; David Schwartz; Jean Boyer; Jeffrey Skolnik; Mark Esser; Rakesh Kumar; Mark Bagarazzi; Ralph Weichselbaum; Michael Spiotto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-03-07       Impact factor: 7.038

6.  Nomograms based on HPV load for predicting survival in cervical squamous cell carcinoma: An observational study with a long-term follow-up.

Authors:  Jing Zuo; Ying Huang; Jusheng An; Xi Yang; Ning Li; Manni Huang; Lingying Wu
Journal:  Chin J Cancer Res       Date:  2019-04       Impact factor: 5.087

7.  HPV Status and Individual Characteristics of Human Papillomavirus Infection as Predictors for Clinical Outcome of Locally Advanced Cervical Cancer.

Authors:  Liana Mkrtchian; Irina Zamulaeva; Liudmila Krikunova; Valentina Kiseleva; Olga Matchuk; Liubov Liubina; Gunel Kulieva; Sergey Ivanov; Andrey Kaprin
Journal:  J Pers Med       Date:  2021-05-27

8.  Low initial human papillomavirus viral load may indicate worse prognosis in patients with cervical carcinoma treated with surgery.

Authors:  Ting Deng; Yanling Feng; Junsheng Zheng; Qidan Huang; Jihong Liu
Journal:  J Gynecol Oncol       Date:  2015-04       Impact factor: 4.401

9.  Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol.

Authors:  Yanhong Wang; Yi Ouyang; Zhigang Bai; Xinping Cao; Jingjing Su; Jing Liu; Qunrong Cai; Qin Xu
Journal:  BMJ Open       Date:  2019-10-07       Impact factor: 2.692

10.  Human papillomavirus (HPV) DNA detection in uterine cervix cancer after radiation indicating recurrence: a systematic review and meta-analysis.

Authors:  Sasidharanpillai Sabeena; Santhosh Kuriakose; Binesh Damodaran; Nagaraja Ravishankar; Govindakarnavar Arunkumar
Journal:  J Gynecol Oncol       Date:  2019-10-22       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.